Red Sun Pharmaceuticals' declared innovative drug Emediffen tablets approved for solid cancer clinical trials
-
Last Update: 2020-06-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, Red Day Pharmaceuticals issued a notice, received the National Drug Administration issued a clinicaltrial(http://notice,company(http://declarednew drugs(http://amedifyfen tablets meet the relevant requirements, approved to carry out physical cancer clinical trialsAbout Emdifin tabletsRed Day Pharmaceuticals is the first oral PD-L1 small molecular inhibitor in the country to be approved for clinical trialsaccording to the announcement of Red Day Pharmaceuticals, compared with the(http://of the single-anti-
drug injected with the same target, which has been approved for listing, amtiffin tablets have the advantages of being able to enter the cell through the cell membrane, to some extent can enter brain tissue for the treatment of brain tumors, can be oral, patient compliance is strong, can avoid adverse reactions caused by macromolecule drugs, etcAt present, there are no approved listing of PD-L1 small molecular inhibitors, Roche subsidiary Genetek research and development of Tecentriq (Tecentriq) short of "T medicine", is the United StatesFDA(http://approved PD-L1 monoantigen, PD-L1 macromolecule inhibitors
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
